Navigation Links
Inflammatory mediator promotes colorectal cancer by stifling protective genes
Date:1/22/2012

HOUSTON - Chronic inflammation combines with DNA methylation, a process that shuts down cancer-fighting genes, to promote development of colorectal cancer, scientists at The University of Texas MD Anderson Cancer Center report today in the advance online publication of the journal Nature Medicine.

The team's connection of these two separate influences eventually may lead to better combination therapies for treating and preventing colorectal cancer.

In animal experiments, researchers found that prostaglandin E2, a chemical that promotes inflammation, accelerates the development of colorectal cancer by shutting down genes that suppress tumors and repair damaged DNA. They also found that while either an anti-inflammatory drug or a demethylating agent reduced the size and number of tumors in mice with colorectal cancer, the most powerful response occurred when both drugs were used together.

"We've known that chronic inflammation increases the risk of developing cancer and progression of disease," said senior author Raymond DuBois, M.D., Ph.D., provost and executive vice president at MD Anderson. "We've also known that tumor-suppressing genes are silenced in human colorectal cancer. However, nobody had made a molecular connection between these inflammatory mediators and changes in gene expression or silencing of genes through affects on DNA methylation."

Cancer prevention potential

The two drugs used in the animal experiments - the anti-inflammatory agent celecoxib (known commercially as Celebrex) and the demethylating agent azacitidine (Vidaza) - are both approved for human use.

"One potential application of our research would be a clinical trial for patients who are at extremely high risk for developing colorectal cancer, such as those with a genetic predisposition, to see if treatment with these agents would decrease their risk," DuBois said.

Prostaglandin E2 and methylation

Prostaglandin E2 (PGE2) is a lipid mediator found at high levels at sites of inflammation where immune cells are aggregating. DuBois and colleagues looked for correlations between levels of PGE2 and a class of enzymes called DNA methyltransferases, which attach methyl groups (one carbon atom joined to three hydrogen atoms) to the promoter region of genes, blocking gene expression.

"We found that levels of PGE2 correlate with levels of two methyltransferases, DNMT1 and DNMT3, in human colorectal cancer specimens," DuBois said.

Subsequent experiments showed PGE2:

  • Directly increased levels of both methylating enzymes in three human colorectal cancer cell lines;
  • Increased the silencing by methylation of the tumor-suppressor gene CNR1 and the DNA repair gene MGMT;
  • Also expanded methylation of a variety of other DNA repair genes, most importantly silencing CDKN2B and MLH1, which repairs DNA mismatches.

PGE2 silences protective genes in mice

Treating mice that are genetically altered to develop colon tumors with PGE2 increased:

  • Levels of the methyltransferase gene expression in tumor cells;
  • Methylation of the four tumor-suppressing genes, which reduced the expression of their corresponding messenger RNA and protein levels in tumor cells; and
  • Size and number of precancerous polyps.

Giving those mice the demethylating agent azacitidine reversed the effect of PGE2 on tumor growth and on the silencing of tumor-suppressing and DNA repair genes.

Mice treated with azacitidine alone experienced a 60 percent reduction in tumors, and those treated with celecoxib alone, a 77 percent tumor reduction. Treatment with both drugs in tandem cut the number of tumors by 93 percent. All three regimens also reduced the average size of tumors; however, the combination therapy led to the greatest decrease, cutting the size of tumors by half.

Same correlations evident in human colorectal cancers

The researchers found that various processes observed in mice - such as inflammation promotion through PGE2 and another inflammatory agent called PTGS2, methlytransferases DNMT1 and DNMT3B, and the methylation of CNR1, MGMT and MLH1 - are all positively associated in human colorectal cancer, as well.

"These mouse studies make us optimistic that we can extrapolate our data to help treat humans," DuBois said. "Improved understanding of PGE2's roles in cancer progression and the regulation of DNA methylation may provide the basis for developing combination therapy to treat targeted groups of patients, and to prevent cancer from occurring or recurring in high-risk groups."


'/>"/>
Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. NIH grant will create behavioral health registry for pediatric inflammatory bowel disease
3. Prozac and Celexa exhibit anti-inflammatory effects
4. Physician's Pain Relief Cream Includes Patented Anti-inflammatory in New Formula
5. Feedback loop explains inflammatory effect on intestinal lining
6. Study Details Machinery of Immune Protection Against Inflammatory Diseases Like Colitis
7. Two New Phytochemicals with Anti-Inflammatory Activity Found in Noni Fruit
8. New research reinforces anti-inflammatory properties of tart cherries
9. First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease
10. POP ROCK BAND Honor Society Drummer Advocates for Inflammatory Bowel Disease Patients on Capitol Hill in Conjunction with World IBD Day
11. Crohn's & Colitis Foundation National Event Helping Women Manage Inflammatory Bowel Disease: Two Women Physician Experts and Researchers in IBD on Interactive Webcast/Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ ... during the summer of 2016. The program was made possible by a Pennsylvania ... Department of Health and Human Services Administration. The broadcast, Use Your Head: ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce ... service for Texas, they are expanding their presence in Dallas. One of the most ... will bring new jobs to the Dallas and Forth Worth market. STAT takes pride ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Australia Glaucoma Surgery Devices Market ... report, "Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices market. The report provides value, ... and average prices (USD) within market segement - ... company shares and distribution shares data for each ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized ... Top Workplaces National Standard. To learn more about ... ... Inc.) ... survey administered by WorkplaceDynamics, LLC, a research firm specializing in organizational ...
Breaking Medicine Technology: